Jump to content

Search the hub

Showing results for tags 'Depression'.

More search options

  • Search By Tags

    Start to type the tag you want to use, then select from the list.

  • Search By Author

Content Type


Forums

  • All
    • Commissioning, service provision and innovation in health and care
    • Coronavirus (COVID-19)
    • Culture
    • Digital health and care service provision
    • Improving patient safety
    • Investigations, risk management and legal issues
    • Leadership for patient safety
    • Organisations linked to patient safety (UK and beyond)
    • Patient engagement
    • Patient safety in health and care
    • Patient Safety Learning
    • Professionalising patient safety
    • Research, data and insight
    • Miscellaneous

Categories

  • Commissioning, service provision and innovation in health and care
    • Commissioning and funding patient safety
    • Health records and plans
    • Innovation programmes in health and care
    • Climate change/sustainability
  • Coronavirus (COVID-19)
    • Blogs
    • Data, research and statistics
    • Frontline insights during the pandemic
    • Good practice and useful resources
    • Guidance
    • Mental health
    • Exit strategies
    • Patient recovery
    • Questions around Government governance
  • Culture
    • Bullying and fear
    • Good practice
    • Occupational health and safety
    • Safety culture programmes
    • Second victim
    • Speak Up Guardians
    • Staff safety
    • Whistle blowing
  • Digital health and care service provision
    • Artificial Intelligence
    • Apps for health and care
    • Teleservices
    • Other health and care software
    • Digital health regulatory bodies/standards/guidance
  • Improving patient safety
    • Clinical governance and audits
    • Design for safety
    • Disasters averted/near misses
    • Equipment and facilities
    • Error traps
    • Health inequalities
    • Human factors (improving human performance in care delivery)
    • Improving systems of care
    • Implementation of improvements
    • International development and humanitarian
    • Patient Safety Alerts
    • Safety stories
    • Stories from the front line
    • Transformative Simulation
    • Workforce and resources
  • Investigations, risk management and legal issues
    • Investigations and complaints
    • Risk management and legal issues
  • Leadership for patient safety
    • Business case for patient safety
    • Boards
    • Clinical leadership
    • Exec teams
    • Inquiries
    • International reports
    • National/Governmental
    • Patient Safety Commissioner
    • Quality and safety reports
    • Techniques
    • Other
  • Organisations linked to patient safety (UK and beyond)
    • Government and ALB direction and guidance
    • International patient safety
    • Regulators and their regulations
  • Patient engagement
    • Consent and privacy
    • Harmed care patient pathways/post-incident pathways
    • How to engage for patient safety
    • Keeping patients safe
    • Patient-centred care
    • Patient Safety Partners
    • Patient stories
  • Patient safety in health and care
    • Care settings
    • Conditions
    • Diagnosis
    • High risk areas
    • Learning disabilities
    • Medication
    • Mental health
    • Men's health
    • Patient management
    • Social care
    • Transitions of care
    • Women's health
  • Patient Safety Learning
    • Patient Safety Learning documents
    • Patient Safety Standards
    • 2-minute Tuesdays
    • Patient Safety Learning Annual Conference 2019
    • Patient Safety Learning Annual Conference 2018
    • Patient Safety Learning Awards 2019
    • Patient Safety Learning Interviews
    • Patient Safety Learning webinars
  • Professionalising patient safety
    • Accreditation for patient safety
    • Competency framework
    • Medical students
    • Patient safety standards
    • Training & education
  • Research, data and insight
  • Miscellaneous

News

  • News

Find results in...

Find results that contain...


Date Created

  • Start
    End

Last updated

  • Start
    End

Filter by number of...

Joined

  • Start

    End

Group

First name

Last name

Country

About me

Organisation

Role

Found 96 results
  1. News Article
    Doctors have warned people on certain mental health medications to take extra precautions as hotter temperatures are expected to return to Britain this weekend. These medications include selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressants in the UK, as well as some antipsychotics. Dr Nick Broughton, NHS England’s national director for mental health, learning disabilities and autism, said: “People taking antipsychotic medication and antidepressants need to be extra cautious during hot weather because some of these medicines can make it harder to keep the body cool. “So, it’s vital that anyone taking medication for their mental health needs should take extra care by keeping out of the sun where possible, drinking plenty of fluids and following any advice from their healthcare professional. “Most importantly, they should not stop taking their medication suddenly and can speak to their GP, pharmacist or mental health team for advice if they need to.” Read full story Source: The Independent, 2 July 2026
  2. News Article
    Oliver Robinson felt he had exhausted conventional therapies when he left the Priory, a private mental health facility where he was treated for depression and addiction between 2019 and 2022. Initially he found relief from a new kind of prescription elsewhere. But by the time he took his own life in November 2023, aged 34, his family believe his medicine was making him worse. In January, an inquest concluded that Robinson’s prescription for medicinal cannabis had “probably contributed to his death”. Catherine McKenna, the coroner for Manchester North, also ruled that his continued use of the prescription, first issued to him in May 2022 by Curaleaf Clinic, a private cannabis provider, “acted as an obstacle” to him receiving appropriate psychiatric and addiction care. His family understand this to be the first ruling of its kind. Now, Oliver’s brother, Alexander Robinson, is launching a campaign for tighter controls on UK private cannabis clinics, including a ban on prescribing to patients with serious mental illness, and greater oversight of a rapidly expanding industry. Alexander worries that others in Oliver’s position could be harmed by accessing medicinal cannabis. “If things do not change he is not going to be the last,” he said. The NHS typically prescribes only a small number of licensed CBMPs – those approved by the medicines regulator – for conditions such as severe epilepsy, multiple sclerosis and chemotherapy-related pain. Legally, specialist doctors can prescribe cannabis-based medicines, including unlicensed products, in NHS and private settings where they judge it clinically appropriate. According to the Care Quality Commission (CQC), the healthcare regulator that oversees private cannabis clinics, most products prescribed privately are unlicensed, meaning they have not been approved by the medicines regulator. Freedom of information data from NHS Business Services Authority showed there were 659,293 unlicensed cannabis products privately prescribed in 2024, more than double the 282,920 issued in 2023. About 80,000 people in the UK are thought to be in receipt of a private prescription. But there is limited evidence that cannabis is a suitable treatment for depression. Read full story Source: The Guardian, 31 March 2026
  3. News Article
    Medical doctors face higher rates of burnout and depression than the general population and are twice as likely to die by suicide. The risks were magnified at the height of the coronavirus pandemic, but the problem existed long before that. More than 40% of physicians, medical school students and residents cite fear of disclosure requirements on licensure forms as a main reason they don’t seek mental health care, according to the American Medical Association (AMA), which has been pushing for legislative and regulatory changes. More states and health systems are amending licensure and credentialing forms to remove mental-health-related questions, such as asking about whether a doctor sought mental health care or treatment, or received a mental health diagnosis. Others have codified such changes into state law. The rationale for asking about mental health was to ensure patient safety. The AMA says safety can be addressed with general language that asks whether a physician is suffering from any impairment that could interfere with patient care. “Having any past diagnosis of a mental health need or a substance use problem is often not relevant,” said AMA President Jesse Ehrenfeld. “The key inquiry ought to be whether the impairment represents a current concern for safety and the physician’s ability to provide competent professional care.” Read full story (paywalled) Source: The Washington Post, 18 February 2025
  4. News Article
    The parents of Thomas Kingston have warned about the side effects of antidepressants after he took his own life. Mr Kingston died from a head injury in February last year at his parents' home in the Cotswolds. A gun was found near his body. The 45-year-old had stopped taking his medication, which had been prescribed by a GP at the Royal Mews Surgery in the days leading up to his death. His parents, Martin and Jill Kingston, are now calling for a change in how patients are prescribed selective serotonin reuptake inhibitors (SSRI) - a widely used type of antidepressant. Martin Kingston told BBC Radio 4's Today programme he believes both the patient and the people close to them should be told more explicitly about the potential side effects of the medication, including what can happen if they stop taking it. The couple want patients to sign a document confirming they've been told about the difficulties of going on and coming off the medication. This could include the patient being told that "it's an extreme case, but it could lead to suicide", Mrs Kingston says. "We'd really like to see that a person, a spouse, a partner, a parent, a close friend, somebody, was going to walk with them through it. Maybe they should be at that signing time." Recording a narrative conclusion at an inquest into his death in December, Katy Skerrett, senior coroner for Gloucestershire, said Thomas Kingston had taken his own life. "The evidence of his wife, family and business partner all supports his lack of suicidal intent," she said at the inquest. "He was suffering adverse effects of medication he had recently been prescribed." In a prevention of future deaths report, made in January, Ms Skerrett said action must be taken over the risk to patients prescribed SSRIs. She questioned whether there was adequate communication of the risks associated with such medication. Read full story Source: BBC News, 4 January 2025 Related reading on the hub: The question that will save lives: Interview with Katinka Blackford Newman, founder of Antidepressant Risks Long-lasting sexual dysfunction after taking antidepressants: Lack of recognition harmful to patients Post-SSRI Sexual Dysfunction: After 30 years, why is the health system still failing to recognise this life-limiting adverse effect?
  5. Content Article
    Electro-Convulsive Therapy , or ECT, is a controversial treatment for a number of severe mental illnesses. In essence, an electric current is passed through the brain and induces an epileptic seizure. Though less frequently used these days, it may still be employed in cases of severe depression and mania resistant to other therapies. After treatment, patients may suffer headaches, feelings of confusion and temporary memory loss. In this article, Dr Paul Lambden summarises the treatment, technique used, the risks and side effects, and longer term outcomes.
  6. Content Article
    Doctors are dying by suicide at higher rates than the general population—somewhere between 300 to 400 physicians a year in the US take their own lives. This article in The Guardian looks at why so many surgeons are dying to suicide and what can be done to stop the trend. It examines how the culture of working long hours and the expectation to be 'superhuman' leads surgeons to suppress their symptoms and avoid seeking help for mental health issues. The article also tells the story of US surgeon and President of the Association of Academic Surgery Carrie Cunningham, who has lived with depression, anxiety and a substance abuse disorder for many years.
  7. Content Article
    In this article, inews columnist Kate Lister looks at the andropause, sometimes called the 'male menopause' that can affect men in their later 40s and early 50s. A gradual decline in testosterone levels can contribute to some men developing depression, loss of sex drive, erectile dysfunction and other physical and emotional symptoms. She looks at current research and views around the issue, highlighting her own bias in initially dismissing the idea and linking this to the societal notion that 'only women are hormonal'. She highlights that although the drop in testosterone men experience is not like the sudden hormonal changes that causes the menopause, men can still experience severe symptoms that require treatment with hormone therapy. "Despite my scoffing at the idea, it turns out that the andropause is very much a real thing that can impact some men very badly. The treatment is exactly the same as it is for women struggling with menopause and perimenopause. It’s hormone replacement therapy: this time in the form of testosterone."
  8. Content Article
    Sexual dysfunction is a common side effect of Serotonergic antidepressants (SA) treatment, and persists in some patients despite drug discontinuation, a condition termed post-SSRI sexual dysfunction (PSSD). The risk for PSSD is unknown but is thought to be rare and difficult to assess. This study, published in the Annals of general psychiatry, aims to estimate the risk of erectile dysfunction (ED) and PSSD in males treated with SAs.
  9. Content Article
    A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin. The objective of this study, published by the International Journal of Safety and Risk in Medicine, was to develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD).
  10. Content Article
    More information about "Long-lasting sexual dysfunction after taking antidepressants: Lack of recognition harmful to patients"
    This opinion piece is by Luke* who suffers from post-SSRI sexual dysfunction (PSSD) after he was prescribed a selective serotonin reuptake inhibitor (SSRI) antidepressant.  Luke introduces the condition, drawing on the experiences that others have shared through PSSD communities, to highlight the devastating impact on patients. He calls for widespread recognition, improved risk communication and better support for sufferers.  *Name has been changed I am Luke. I’ve been suffering with PSSD for more than 10 years. My life has been drastically altered. I am now an active member of the PSSD UK patient group and PSSD Network, through which I help raise awareness and support fellow sufferers in the hope that our situations can improve and a cure can be found. Post-SSRI sexual dysfunction Post-SSRI sexual dysfunction (PSSD) is a disorder in which individuals, who have been administered selective serotonin reuptake inhibitors (SSRIs) or other serotonin reuptake-inhibiting (SRI) drugs, experience persistent changes in sexual function and/or genital numbness for an extended period after ceasing to take the drug. Although it is most commonly caused by SSRIs (a widely prescribed group of antidepressants), cases have also been reported following the use of serotonin-norepinephrine reuptake inhibitors (SNRIs), SRI tricyclic antidepressants, SRI antihistamines, tetracycline antibiotics such as doxycycline, and analgesics such as tramadol.[1] Antidepressants have been known for some time to impact sexual function (while being taken) and this risk is included, to some extent, in the medication information. However, the risk of long-term impact to sexual function, after a person ceases to take the medication, has lacked widespread recognition for many years despite being highlighted by patients and researchers around the world.[2,3,4] Awareness remains poor despite some formal recognition In 2019, the European Medicines Agency formally recognised that sexual dysfunction can persist beyond discontinuation of SSRI and SNRI antidepressants[5]. The Pharmacovigilance Risk Assessment Committee stated: “Sexual dysfunction, which is known to occur with treatment with SSRIs and SNRIs and usually resolves after treatment has stopped, can be long-lasting in some patients, even after treatment withdrawal.”[6] Despite this, awareness is still very poor and formal recognition still does not exist in most countries. Although some urologists and sexual medicine specialists seem familiar with the condition, many general practitioners have not heard of PSSD. Psychiatrists often dispute the legitimacy of the illness or claim that it is exceedingly rare, but don’t have any data to prove the prevalence. For a long time, PSSD has been dismissed by many doctors as being a psycho-somatic illness – for example, the result of untreated depression. It is still typical for patients to be disbelieved like this, despite the clear distinction between the diagnostic criteria for clinical depression and the diagnostic criteria that has been developed by researchers for PSSD.[7] The latter outlines two ‘necessary’ criteria for PSSD to be diagnosed. (1) Prior treatment with a serotonin reuptake inhibitor. (2) An enduring change in somatic (tactile) or erogenous (sexual) genital sensation after treatment stops. ‘Additional’ criteria includes: Enduring reduction or loss of sexual desire. Enduring erectile dysfunction (males). Enduring inability to orgasm or decreased sensation of pleasure during orgasm. The problem is present for ≥3 months after stopping treatment. Also listed are both sexual and non-sexual symptoms of PSSD as per below: genital pain reduced nipple sensitivity decreased or loss of nocturnal erections (males) reduced ejaculatory force (males) flaccid glans during erection (males) decreased vaginal lubrication (females) emotional numbing depersonalisation other sensory problems involving skin, smell, taste or vision. The lack of awareness amongst the medical community also means that there is no available treatment or support for PSSD sufferers, who will often turn to the internet for help. Many sufferers, desperate to improve things, end up trialling a variety of drugs and supplements, some of which seem to make symptoms permanently worse. Medication labelling and communicating risk Only Canada and the EU countries (plus post-Brexit Britain) require any warning of persistent sexual side effects on the drug labels. In the rest of the world, there are still no warnings about persistent sexual side effects of SRI antidepressants. Non-English speakers have additional challenges finding information about PSSD, even online. With so many doctors still unaware of the illness, the risks are frequently not being communicated to patients, meaning they can’t possibly give informed consent when taking antidepressants as prescribed. A community abandoned (Image: PSSD Network photo campaign) PSSD sufferers in our communities are absolutely desperate. They feel lied to, mistreated and abandoned. We know from those with lived experience that PSSD often includes complete loss of libido and ability to function sexually, complete emotional dysfunction (anhedonia) and cognitive dysfunction. This frequently results in the breakup of existing romantic relationships and extreme difficulty in forming new ones. PSSD sufferers can find it hard to bond and connect emotionally with others due to emotional dysfunction, and struggle to find any kind of enjoyment in activities that were previously enjoyable. It can cause alienation from friends and family. Some are unable to continue working due to severe cognitive impairments. They often describe it as like being chemically castrated and lobotomised, bearing no resemblance to the experience of suffering clinical depression. Despite PSSD being a result of a prescribed medication, sufferers frequently report being gaslit by doctors, who have typically claimed that their complaints are really symptoms of underlying depression. However, patients prescribed SRI antidepressants for conditions as diverse as irritable bowel syndrome, nerve pain and premenstrual dysphoric disorder have also developed PSSD. These harmful attitudes, and the lack of any known treatment or available support, makes PSSD sufferers feel like there is no hope. Some have ended up taking their lives as a result of PSSD, despite never having been suicidal at any point in their lives previously. Improvements needed Thankfully, further research[8] and an increase in media coverage in the UK,[9] including a recent Panorama documentary, are helping draw attention to this issue and change attitudes. There needs to be further action taken if we are to see long-lasting improvements in the care and treatment of patients with PSSD. I would like to see: Widespread acknowledgement of the condition. Doctors provided with up-to-date information and training (informed by lived experience) on the dangers of antidepressants and how to support patients. Warnings on instructions for the medications updated and prescribing clinicians alerted to ensure patients are adequately informed. An awareness and media campaign launched targeting patients, prescribers and the public. Funding secured for research that helps us gain an understanding of the underlying pathophysiology, identification of a diagnostic biomarker and, eventually, a cure for PSSD. Doctors listening to patients so they can understand how PSSD is a life-changing condition and be able to refer to support services. PSSD is a modern-day tragedy which devastates the lives of sufferers and their families. There are people with this condition who still don’t know that there is a name for it and more of them come out of the woodwork with each new media mention. It is vital that the medical community begins listening and supporting sufferers, and researching a cure before more lives are lost. How you can help I’d encourage you to visit the PSSD Network website to help you understand PSSD and our campaigning work. Clinicians can offer their support by watching this powerful podcast made by PSSD sufferers, discussing the issue with their healthcare organisation and by joining the list of doctors and specialists acknowledging the condition. Researchers can get involved by contacting PSSD network or RxISK. Patients can speak out about PSSD using the initiatives under the ‘take action’ section of the PSSD Network website. Anyone can donate to research via the RxISK website or PSSD Network. References Healy D, Bahrick A, Bak M et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76. Healy D. Post-SSRI sexual dysfunction & other enduring sexual dysfunctions. Cambridge University Press, 2019. Access online 18/09/2023. Healy D, Le Noury J and Mangin D. Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases. Int J Risk Saf Med. 29 (2018) 125–134. PSSD UK. Our stories. Accessed online 18/09/2023. Pharmacovigilance Risk Assessment Committee (PRAC). New product information wording – Extracts from PRAC recommendations on signals. European Medicines Agency. 2019. Lane C. Post-SSRI Sexual Dysfunction Recognized as Medical Condition. Psychology Today. 2019. Accessed online 18/09/2023. Healy D, Bahrick A, Bak M et al. Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022;33(1):65-76. Ben-Sheetrit J, Hermon Y, Birkenfeld S at el. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry 22, 15 (2023). 9. RxISK. Media Articles: PSSD & Related Conditions. Accessed online 18/09/2023. Do you have an experience or insights to share? Have you ever experienced adverse and/or long-lasting side effects of a medication you were prescribed that you didn't feel you adequately warned about beforehand? Perhaps you are a prescribing clinician who can share some of the challenges and complexities involved in medication safety? What did you think of the points raised and calls to action in Luke's article? Please comment below (sign up first for free) or get in touch with us at [email protected] to tell us more.
  11. News Article
    ChatGPT , the artificial intelligence tool, may be better than a doctor at following recognised treatment standards for depression, and without the gender or social class biases sometimes seen in the physician-patient relationship, a study suggests. The findings were published in Family Medicine and Community Health. The researchers said further work was needed to examine the risks and ethical issues arising from AI’s use. Globally, an estimated 5% of adults have depression, according to the World Health Organization. Many turn first to their GP for help. Recommended treatment should largely be guided by evidence-based clinical guidelines in line with the severity of the depression. ChatGPT has the potential to offer fast, objective, data-based insights that can supplement traditional diagnostic methods as well as providing confidentiality and anonymity, according to researchers from Israel and the UK. Read full story Source: The Guardian, 16 October 2023
  12. Content Article
    Public and patient expectations of treatment influence health behaviours and decision-making. This study aimed to understand how the media has portrayed the therapeutic use of ketamine in psychiatry. It found that ketamine treatment was portrayed in an extremely positive light, with significant contributions of positive testimony from key opinion leaders (e.g. clinicians). Positive research results and ketamine's rapid antidepressant effec were frequently emphasised, with little reference to longer-term safety and efficacy. The study concluded that information pertinent to patient help-seeking and treatment expectations is being communicated through the media and supported by key opinion leaders, although some quotes go well beyond the evidence base. Clinicians should be aware of this and may need to address their patients’ beliefs directly.
  13. Content Article
    Samuel Howes was 17 when he died by suicide in September 2020. Samuel had ongoing mental health issues including anxiety and depression. This led to his use of drugs and dependency on alcohol, which in turn further worsened his mental health. This blog by his mother Suzanne details her experience of the final day of the inquest into her son's death, which found multiple failings on the part of Child and Adolescent Mental Health Services (CAMHS), social services and the police.
  14. Content Article
    Technologies to assist with diabetes treatment and care have evolved rapidly over the past two decades. With each new innovation coming to the market, there are hopes that technologies will solve the numerous, complex issues related to diabetes. However, although it has been demonstrated that overall, these technologies—when available—bring major benefits to people living with diabetes, they do not make the condition disappear. This article in Diabetes Epidemiology and Management discusses the interconnections between technologies and diabetes distress, an often under-acknowledged consequence of the continuous demands of diabetes.
  15. News Article
    Three in four NHS staff have struggled with a mental health condition in the last year, according to a new poll. A survey of workers carried out by NHS Charities Together over medics’ mental health comes as healthcare leaders were forced to reverse cuts to NHS Practitioner Health, a service for medics. A backlash from NHS staff over the proposed cuts forced health secretary Victoria Atkins to intervene. In the new poll of more than 1,000 NHS staff, 76% said they have experienced a health condition in the last year with 52% reporting anxiety, 51% reporting low mood, while 42% of respondents also said they’d experienced exhaustion. Meanwhile, the most recent NHS data shows the most common reasons for staff sickness are anxiety, stress, depression or other psychiatric conditions, with more than 586,600 working days lost over this in November 2023. NHS Practitioner Health began as a mental health service for GPs but has since expanded to other specialities following funding from NHS England. However, last week the provider announced this national funding was due to end, so its service would be reduced. NHS England said the decision was so it could review the services available for all NHS staff. However, it was forced to u-turn on the decision and agreed to provide funding for an additional year. Read full story Source: The Independent, 17 April 2024
  16. News Article
    Women who experience depression during pregnancy or in the year after giving birth are at a higher risk of suicide and attempting suicide, researchers have warned. The British Medical Journal study warned that women who develop perinatal depression are twice as likely to die compared to those who don’t experience depression. Suicide was the leading cause of death for women in the UK in 2022 between six weeks and one year after birth, while deaths from psychiatric causes accounted for almost 40 per cent of maternal deaths overall, according to a Perinatal Mortality Surveillance report. Last year an analysis by Labour revealed 30,000 women who were pregnant were on waiting lists for specialist mental health support. The number of women waiting rose by 40 per cent between August 2022 and March 2023. The most recent NHS data shows in September 2023, 61,000 women accessed perinatal mental health services. For 2023-24, the health service must hit a target to have 66,000 women accessing care. In August 2023, the Royal College of Midwives published a research warning half of anxiety and depression cases among new and expectant mothers were being missed amid NHS staff shortages in maternity care. Read full story Source: The Independent, 11 January 2024
  17. Event
    until
    The past couple of years have placed enormous pressures on the mental health and wellbeing of the population. The current cost of living crisis is having a significant impact on people’s state of mind with millions feeling stressed about rising food and energy prices as we head into winter. Delivered by Maximus, the Access to Work Mental Health Support Service, funded by the Department for Work and Pensions, can help employees and employers during this difficult time with their mental health. Completely confidential, the service is available at no charge to anyone with depression, anxiety, stress or other mental health issues, affecting their work. Remploy already helped thousands of people across England, Scotland and Wales, to remain in, or return to work, so our expertise speaks for itself. Led by Bethany Kimberley and Kaylena Mushen, this webinar will introduce the service, covering facts and statistics around mental health. It also looks at the service’s aims, eligibility criteria and referral process, plus what support and workplace adjustments are available at home, in an office, or other place of work. The session will also introduce and additional service, offering virtual one-to-one support appointments for employees. Learn how to gain access to fully-funded expert advice and support for up to nine months, which includes – A well being plan to help employees stay in, or attend work. Ideas for suitable workplace adjustments. Tailored coping strategies. Facts and statistics around mental health. Aims of the service. Details of the eligibility criteria and referral process. The support and interventions available. Register
  18. News Article
    Open letter to government from experts and politicians says rising usage ‘is a clear example of over-medicalisation’. Medical experts and politicians have called for the amount of antidepressants being prescribed to people across the UK to be reduced in an open letter to the government. The letter coincides with the launch of the all-party parliamentary group Beyond Pills, which aims to reduce what it calls the UK healthcare system’s over-reliance on prescription medication. Read full story Source: Guardian, 5 December 2023
  19. News Article
    The number of adults experiencing depression has almost doubled during the pandemic, according to new figures. Data from the Office for National Statistics showed that almost one in five adults (19.2 per cent) were likely to be experiencing some form of depression in June. This had risen from around one in 10 (9.7%) between July 2019 and March 2020, before the imposition of the nationwide lockdown. Dame Til Wykes, a professor of clinical psychology and rehabilitation at King’s College London, warned of a looming “mental health crisis” once the pandemic passes. “This study tells us, yet again, that we might have a mental health crisis after this pandemic. The social effects of distancing and isolation for some affects their emotional wellbeing. Dr Billy Boland, chairman of the General Adult Faculty at the Royal College of Psychiatrists, said the UK’s mental health services would be faced with a “tsunami of referrals” in the coming months. “Isolation, bereavement and financial insecurity are some of the reasons why the nation’s mental health has deteriorated since the start of the pandemic. “The government must speed up the investment to mental health services if we are to treat the growing numbers of people living with depression and other mental illnesses.” Read full story Source: The Independent, 18 August 2020
  20. News Article
    The coronavirus lockdown has provoked a mental health crisis among the LGBTQ community, with younger people confined with bigoted relatives the most depressed, researchers found. A study of LGBTQ people’s experience during the pandemic, by University College London (UCL) and Sussex University, found 69% of respondents suffered depressive symptoms, rising to about 90% of those who had experienced homophobia or transphobia. Almost 10% of people reported they felt unsafe in their homes. The study called for more government support for LGBTQ charities, which have experienced significant rises in demand since the start of the pandemic. It warned: “Poor LGBTQ+ mental health may remain unchecked without a substantial policy commitment and funding directed to ameliorating health inequalities exacerbated by the pandemic.” Read full story Source: The Guardian, 5 August 2020
  21. News Article
    People who were seriously ill in hospital with coronavirus need to be urgently screened for post-traumatic stress disorder (PTSD), leading doctors say. The Covid Trauma Response Working Group, led by University College London and involving experts from south-east England, said those who had been in intensive care were most at risk. The experts said regular check ups should last at least a year. More than 100,000 people have been treated in hospital for the virus. The experts say tens of thousands of these would have been seriously ill enough to be at risk of PTSD. The working group highlighted research which showed 30% of patients who had suffered severe illnesses in infectious disease outbreaks in the past had gone on to develop PTSD, while depression and anxiety problems were also common. Tracy is just one of many people who has been left with psychological scars from her coronavirus experience. She was admitted to Whittington Hospital in north London in March and spent more than three weeks there - one of which was in intensive care. "It was like being in hell. I saw people dying, people with the life being sucked from them. The staff all have masks on and all you saw was eyes - it was so lonely and frightening." Since being discharged in April the 59-year-old has been struggling to sleep because of the thought she will die and she has constantly suffered flashbacks. She is now receiving counselling. Read full story Source: BBC News, 29 June 2020
  22. News Article
    The use of electroconvulsive therapy (ECT) to treat depression should be immediately suspended, a study says. ECT involves passing electric currents through a patient's brain to cause seizures or fits. Dr John Read, of the University of East London said there was "no place" for ECT in evidence-based medicine due to risks of brain damage, but the Royal College of Psychiatrists said ECT offers "life-saving treatment" and should continue in severe cases. The National Institute for Health and Care Excellence (NICE) currently recommends the use of ECT for some cases of moderate or severe depression as well as catatonia and mania. However, peer-reviewed research published in the journal Ethical Human Psychology and Psychiatry concludes "the high risk of permanent memory loss and the small mortality risk means that its use should be immediately suspended". In response to the study, the Royal College of Psychiatrists said ECT should not be suspended for "some forms of severe mental illness". Dr Rupert McShane, chair of the college's Committee on ECT and Related Treatments, said there was evidence showing "most people who receive ECT see an improvement in their condition". "For many, it can be a life-saving treatment," he said. "As with all treatments for serious medical conditions - from cancer to heart disease - there can be side-effects of differing severity, including memory loss." Read full story Source: BBC News, 3 June 2020
  23. Content Article
    Everybody responds differently to the stresses and strains of modern life. We all need and, to a degree, thrive on pressure: it gives us energy, helps with performance and inspires confidence. But excessive pressure can lead to stress. Stress may become a problem when someone feels they don’t have the resources to cope with the demands placed upon them. Harmful levels of stress can lead to a mental health condition such as anxiety or depression. This booklet from the Devon Partnership NHS Trust aims to give you some very practical information and guidance – and provides spaces for you to make notes so you can make it work for you.
  24. Content Article
    Students learn about medication and non-medication strategies for reducing symptoms of depression and other neuropsychiatric symptoms (e.g. agitation, anxiety) in people with dementia. While non-medication strategies are often emphasised as being preferable, often we lack the time and resources to facilitate their implementation. There is also a sense that people believe that medications worked better—even though we don’t really know if this is true since studies comparing medication to non-medication strategies are rare. The problem with prescribing medications in this patient population is that medications are associated with potentially catastrophic side effects (e.g. falls and fractures). Jennifer Watt and Zahra Goodarzi  undertook a research project looking at the comparative efficacy of interventions for reducing symptoms of depression in people with dementia. Based on their clinical experience as geriatricians, they hypothesised that non-medication strategies could effectively reduce symptoms of depression because they are addressing its underlying causes. 
  25. News Article
    The world is likely to face a global crisis in poor mental health after the coronavirus pandemic has passed, experts have warned. Two dozen mental health scientists including neuroscientists, psychiatrists, psychologists, and public health experts have warned of the long-term impact of the virus on people’s mental health and demanded governments prioritise research to come up with evidence-based treatments. They also called for real-time monitoring of mental health in the UK and across the world in order to gauge the severity of the expected increase in poor mental wellbeing. Their warning, in the journal Lancet Psychiatry, comes as a new Ipsos Mori survey carried out at the end of March revealed people’s mental health was already being affected by the UK lockdown and self-isolation policy. Read full story Source: The Independent, 16 April 2020

© 2026 Patient Safety Learning. All rights reserved.

Patient Safety Learning is registered as a charity with the Charity Commission Registration number 1180689.

×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.